The SEC Recommends Closing Cassava Sciences Investigation ( NASDAQ : SAVA )

In our series of letters from African journalists, ablokhin editor explains why the company behind the Alzheimer's disease drug Simufilam is selling for an incredible $150 Billion (£76bn) in the US stock market for the first time.

Source: seekingalpha.com
Published on 2022-09-23